Brad Nelson

Scientific Co-Director, BC Cancer Immunotherapy Program (Deeley Research Centre)
Professor of Biochemistry/Microbiology, University of Victoria
Professor of Medical Genetics, University of British Columbia

Full Biography

Projects at BioCanRx

Enabling a Phase I/II Multicenter Clinical Trial of a Novel Single Domain (sd)CD-22-specific Camelid-derived Chimeric Antigen Receptor (CAR) T-cell Therapy

Interrogation of Biomarkers in Patient Samples from a Phase Ib Trial of the Immune Checkpoint Inhibitor, Avelumab, in Combination with SMAC Mimetic Debio1143

Adoptive T cell therapy targeting patient-specific driver mutations in lymphoma

Recent Articles

Introducing the winners of BioCanRx’s 2019 Summer Studentships

Summit4CI 2018: The HQP Experience

Meet Two of BioCanRx’s Summer Students

Removing obstacles to innovation: BioCanRx core facilities provide essential manufacturing, immune analysis services

Moving from the lab to the clinic